Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 8,201–8,300 of 10,906
Kattih, Z., Moore, J., Stefanov, D. G., Makkar, P., & Laktičová, V. (2024) · Clinical Immunology Communications · doi:10.1016/j.clicom.2024.01.001 · Cited by 2
Immunobiology and immunotherapy of COVID-19
Lundstrom, K. H. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.12.002 · Cited by 3
Chen, W., Hu, S.-Y., Cheng, C., Shen, C., Chuang, H.-Y., Ker, C.-R., Sun, D.-J., & Shen, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1415561 · Cited by 2
Adhikari, S., Sony, K. C., Dev, S., Bhandari, S., Parajuli, P., Poudel, M. B., Adhikari, Y. R., & Poudel, B. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001351 · Cited by 3
The rational design of mRNA vaccine: From empirical method to artificial intelligence-based design
Hu, Y., Pu, C., Liu, B., & Zhang, L. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0478 · Cited by 2
Immunogenic Comparison of Nucleic Acid-Based Vaccines Administered by Pyro-Drive Jet Injector
Tai, J. A., Nishikawa, T., Hayashi, H., Kuan, Y.-D., Yamashita, K., & Nakagami, H. (2024) · Vaccines · doi:10.3390/vaccines12070757 · Cited by 5
Wen, J., Moon, J., Tucciarone, L., Bu, T.-H., Sun, A. Y., Miller, R., Timis, J., Wu, L., Smith, D. M., Shresta, S., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01421-z · Cited by 2
de León, U. A.-P., Pérez, Á. G. C., & Avila-Vales, E. J. (2023) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023484 · Cited by 2
A case for conducting business-to-business experiments with multi-arm multi-stage adaptive designs
Legare, J., Yao, P., & Lo, V. S. Y. (2022) · Journal of Marketing Analytics · doi:10.1057/s41270-022-00177-4 · Cited by 3
Nanteza, M. B., Nanyonjo, G., Kyakuwa, N., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312377 · Cited by 2
Immunomodulatory Delivery Materials for Tissue Repair
Est-Witte, S. E., Jain, M., Ben‐Akiva, E., Yang, J., Warren, T., Tzeng, S. Y., & Green, J. J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501400 · Cited by 4
Merits and Demerits of COVID-19 Vaccines
El-Nimr, N. (2021) · Journal of High Institute of Public Health · doi:10.21608/jhiph.2021.150582 · Cited by 3
Li, J., Xiao, H., Zhang, C., Liu, G., & Liu, X. (2024) · European Journal of Immunology · doi:10.1002/eji.202350916 · Cited by 2
Ulaya, G., Kabaghe, A. N., Saussier, C., et al. (2024) · medRxiv · doi:10.1101/2024.12.23.24319583 · Cited by 2
van den Berg, J. M., Blom, M. T., Overbeek, J. A., Remmelzwaal, S., Herings, R. M. C., & Elders, P. J. M. (2025) · Vaccines · doi:10.3390/vaccines13060564 · Cited by 3
“Since the introduction of COVID-19 vaccines in 2020, starting with the approval of BNT162b2 in December 2020, these have shown high efficacy in preventing severe COVID-19, but their effectiveness in preventing SARS-CoV-2 infection is comparatively low [1–4].”
Eckermann, S. D. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1085319 · Cited by 2
Khan, M. S., Shakya, M., & Verma, C. K. (2024) · VirusDisease · doi:10.1007/s13337-024-00894-7 · Cited by 3
Le, T., Jia, B., Sun, C., Zhou, Y.-F., Qi, Y., Liu, H., Bian, H., Tian, C., Wang, J., Xue, F., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127841 · Cited by 4
Adverse Reactions of COVID-19 Vaccines
Jo, E. (2022) · Journal of Clinical Otolaryngology Head and Neck Surgery · doi:10.35420/jcohns.2022.33.2.92 · Cited by 2
Study of functional lipid nanoparticles for mRNA delivery using new ionizable tocopherol derivatives
Choi, M., Jung, O., Lee, E., & Choi, J. S. (2024) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12909 · Cited by 2
Immunoassays for the Diagnosis of Infectious Diseases
Theel, E. S. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0009.pub2 · Cited by 3
Design of cross-reactive antigens with machine learning and high-throughput experimental evaluation
Chesterman, C. C., Desautels, T., Sierra, L. F. C., Arrildt, K. T., Zemla, A. T., Lau, E. Y., Sundaram, S., Laliberte, J. P., Chen, L., Ruby, A., et al. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1580967 · Cited by 3
Li, J. C., Siglin, J., Marshall, M. S., Stemmer-Rachamimov, A. O., Bloom, S. M., & Blumenthal, K. G. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac499 · Cited by 2
Choi, J., Carroll, A., Nguyen, V. H., Michta, M., Zhang, X. Q., Lim, Y., & Chung, R. T. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70733 · Cited by 4
Perdomo, A. D., Garrafa-Núñez, M., Meza-Caballero, M. E., Villanueva, G. P., Balbás, Y. S., & Sánchez-Paniagua-Castillo, J. (2021) · Medicina y Seguridad del Trabajo · doi:10.4321/s0465-546x2021000100002 · Cited by 7
RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review
Generalov, E. A., Shevelev, A. B., Romanov, D., Tarasova, O. A., & Pozdniakova, N. V. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040431 · Cited by 3
Purohit, A., Chhatre, N., Qazi, B., Kumar, V. R., Haldar, S., & Bhattacharya, A. (2025) · Small · doi:10.1002/smll.202412218 · Cited by 2
da Silva, J. V. G. O., & Santos, E. D. O. (2026) · Archives of Microbiology · doi:10.1007/s00203-025-04706-4 · Cited by 2
“…vaccine based on adenovirus and mRNA-based vaccines (Pfizer–BioNTech and Moderna) approved for emergency use in the COVID-19 pandemic (Baden 2021; Polack 2020 ); (iii) cold plasma as an efficient solution for virus inactivation has been applied to viruses such as noro-virus,…”
Circular nucleic acids at the host-virus interface: from immune modulation to therapeutic innovation
Lou, J., LIU, J., Zhang, D., & Hao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1751068 · Cited by 2
Advancing Protein‐Coding RNA Engineering: From Structural Refinement to Biomedical Implementation
Lu, X., Li, S., Chi, Y., Lin, S., Yuan, H., Lin, Z., Xiao, Y., Yin, H., Zuo, X., Cheng, R., et al. (2025) · Biotechnology Journal · doi:10.1002/biot.70038 · Cited by 2
Schroth, D., Garg, R., Bocova, X., Hansmann, J., Haass, M., Yan, A. T.-K., Fernando, C., Chacko, B. R., Oikonomou, A., White, J. A., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1204232 · Cited by 2
Hu, F., Gong, R., Chen, Y., Zhang, J., Hu, T., Chen, Y., Zhang, K., Shang, M., & Cai, Y. (2021) · Vaccines · doi:10.3390/vaccines9111221 · Cited by 2
Acceptance of covid-19 vaccine among the healthcare providers in India
Samantaray, A., Dora, S., Sinha, A. K., & Panda, P. S. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2165_21 · Cited by 2
Benuni, N., Kotusov, A., Adzhieva, F., Кучер, А., Tolmacheva, K. A., Dushuk, V. N., & Maslennikov, R. V. (2022) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2022-32-3-23-28 · Cited by 2
Liu, Q., Zhang, Y., Guo, Q., Sun, J., Pan, Z., Lin, S., Fan, K., Luo, T., Li, Y., Gong, N., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502225 · Cited by 2
Vaccination Against COVID-19: Emerging Issues and Future Prospects
Onischenko, G. G., Sizikova, T. E., Lebedev, V. N., & Borisevich, S. V. (2021) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn1672 · Cited by 4
Urology practice during the COVID-19 vaccination campaign
Ficarra, V., Novara, G., Giannarini, G., et al. (2021) · Urologia Journal · doi:10.1177/03915603211016321 · Cited by 2
Post-vaccination SARS-cov-2 infection in nursing home residents, Bordeaux, France
Lartigau, M., Ouattara, E. N., Tumiotto, C., Wodrich, H., Busson, L., Trimoulet, P., Thiel, E., Nouzille, M., Dubos, M., Lafon, M., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105134 · Cited by 2
Sudden Hearing Loss Waves: The Effect of COVID-19 Infection and Vaccination on the Inner Ear
Tawk, K., Tawk, A., & Abouzari, M. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-61939-7_15 · Cited by 3
COVID-19 vaccine and immune response
Hıntıstan, S., & DEMİRAĞ, H. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00023 · Cited by 3
Li, R., Li, Y., Zou, Z., Liu, Y., Li, X., Zhuang, G.-H., Shen, M.-W., & Zhang, L. (2021) · medRxiv · doi:10.1101/2021.06.24.21259370 · Cited by 2
de Lima, V. A., Nunes, J. P. S., Rosa, D. S., Ferreira, R. D. S., Oliva, M. L. V., Andreata‐Santos, R., Duarte-Barbosa, M., Janini, L. M., Maricato, J. T., Akamatsu, M. A., et al. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1353 · Cited by 1
Wang, L., Zhuang, L., Li, T., Hara, H., Cooper, D. K. C., Leng, J., Pan, D., Zheng, S., Wang, Y., Xu, X. X., et al. (2025) · Xenotransplantation · doi:10.1111/xen.70050 · Cited by 2
“These vaccines include traditional inactivated virus formulations [20, 21] and mRNA-based vaccines [22, 23].”
Wu, Y., Jia, X., Wu, N., Zhang, X., Wu, Y., Liu, Y., Zhou, M., Shen, Y., Li, E., Wang, W., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.030 · Cited by 2
Yamamoto, S., Matsuda, K., Maeda, K., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae519 · Cited by 2
Liu, C., Wang, X., Zheng, Y., Gao, X., Jin, J., Cheng, X., He, Y., & Wang, P. G. (2025) · Vaccines · doi:10.3390/vaccines13070764 · Cited by 2
“Messenger RNA (mRNA) lipid nanoparticles (LNP) vaccines have been recognized as a next-generation vaccine due to the safety and effectiveness in combating the pandemic of coronavirus disease 2019 (COVID-19) [10,11].”
Feng, J., Wang, W.-J., Jin, P., Zheng, H., Jin, L., Xia, X., Zhang, X., Li, Z.-P., Li, J., & Zhu, F. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2230760 · Cited by 2
Deletion disrupts a conserved antibody epitope in a SARS-CoV-2 variant of concernPreprint
Rennick, L. J., Robinson‐McCarthy, L. R., Nambulli, S., Duprex, W. P., & McCarthy, K. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.05.434168 · Cited by 2
Powelson, I. A., Kaufmann, R. A., Chida, N. M., & Shores, J. T. (2021) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2021.07.002 · Cited by 2
Thaman, P., Tafuto, B. A., Gélinas, C., Gaur, S., & Neubauer, J. A. (2022) · Journal of Clinical and Translational Science · doi:10.1017/cts.2022.383 · Cited by 2
Brave new RNA world(s): from prebiotic chemistry to gene regulation and RNA technology
Flores-García, A. A., Hernandez-Rodriguez, A., López-Brito, E. I., Nava-Domínguez, D. F., Pasapera, S. P., Pazos-Murillo, R. F., Pineda-Diaz, T., & Vázquez-Salazar, A. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1813517 · Cited by 2
Kim, H., Brosseau, Q., Radzio, J., Wang, J., Muramatsu, H., Kuang, D., Grady, M. S., Chen, H. I., Wolf, J. A., Ulyanova, A. V., et al. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1359700 · Cited by 2
Chen, G., Ren, Q., Zhou, J., Zhou, Y., Luo, H., Wang, Y., Li, X., Zhao, B., & Li, X. (2022) · Vaccines · doi:10.3390/vaccines10050706 · Cited by 2
Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection
(2021) · doi:10.1101/2021.04.16.21255614 · Cited by 2
Brisotto, G., Montico, M., Turetta, M., Zanussi, S., Cozzi, M. R., Vettori, R., Boschin, R. B., Vinante, L., Matrone, F., Revelant, A., et al. (2023) · Viruses · doi:10.3390/v15061276 · Cited by 2
Engineered migrasomes provide a robust and thermally stable vaccination platformPreprint
Wang, D., Wang, H., Wan, W., et al. (2024) · eLife · doi:10.7554/elife.97621 · Cited by 2
“The huge success of mRNA vaccines in the fight against the Covid-19 pandemic further supports the importance of developing vaccine platforms based on different underlying biological mechanisms ( Park et al., 2021 ; Polack et al., 2020 ; Baden et al., 2021 ; Gui et al., 2023 ).”
How Should Anesthesiologists Face Coronavirus Disease 2019?
Feng, L., Fu, S., Zhang, P., Yao, Y., Feng, Z., Zhao, Y., & Luo, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.890967 · Cited by 2
Шелковникова, Т. А., Maksimova, A. S., Ryumshina, N. I., et al. (2022) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2022-37-4-105-113 · Cited by 2
The Behavioral Immune System and Vaccination Intentions During the Coronavirus PandemicPreprint
Karlsson, L. C., Soveri, A., Lewandowsky, S., et al. (2021) · doi:10.31234/osf.io/r8uaz · Cited by 2
Burghardt, T., Thalmayr, S., Obeser, L., Pöhmerer, J., Yazdi, M., Höhn, M., Völkl, M., Sieber‐Schäfer, F., Zahler, S., Merkel, O. M., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c19141 · Cited by 2
Forte, S., Toepp, A. J., Bray, R. A., Baran David, A., Gilgannon, L. T., Williams, T., Chen, S., Hooman, S., Gebel Howard, M., Herre John, M., et al. (2022) · Archives of Organ Transplantation · doi:10.17352/2640-7973.000019 · Cited by 2
Алексеевич, С. А., Витальевич, Г. Д., Меркулов, В. А., & Бондарев, В. П. (2022) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2022-22-4-361-381 · Cited by 2
Self, W. H., Stewart, T. G., Wheeler, A. P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-227796/v1 · Cited by 2
A COVID-19 Overview from the Perspective of the Brazilian Kidney Transplantation Program
Requião‐Moura, L., Foresto, R. D., de Sandes‐Freitas, T. V., et al. (2023) · COVID · doi:10.3390/covid3080083 · Cited by 2
Chan, T. K. (2022) · Journal of Global Health · doi:10.7189/jogh.12.03004 · Cited by 2
SARS-CoV-2 vaccine-elicited immune responses in solid organ transplant recipients
Seo, E., Shin, E., & Jung, M. K. (2024) · Clinical Transplantation and Research · doi:10.4285/ctr.24.0062 · Cited by 2
Effects of SARS-CoV-2 Vaccines on Sperm Quality: Systematic Review
Li, G., Zhang, R., Song, B., Wang, C., Shen, Q., He, X., & Cao, Y. (2023) · JMIR Public Health and Surveillance · doi:10.2196/48511 · Cited by 3
Hospital-Based RNA Therapeutics
Damase, T. R., Sukhovershin, R. A., Zhang, M., Kiss, D., & Cooke, J. P. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_4 · Cited by 5
Yu, H., Yang, Y., Lin, P., Liu, C., Wen, Y., Huang, Z., Fang, Z., Hu, Z., & St, H. (2026) · Nature Communications · doi:10.1038/s41467-026-69972-2 · Cited by 7
Pool, S. N. T., Shroff, E. H., Chetty, A., Lewis, L., Yende‐Zuma, N., & Karim, S. S. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299747 · Cited by 3
Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward
Wang, W., Xu, D., Ding, J., Pan, Y., Wang, F., Su, S., Xia, P., Zhang, S., & Zhang, W. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10614-1 · Cited by 2
“Lipid nanoparticles play a critical role in mRNA vaccine delivery by demonstrating their capacity to properly stabilize therapeutic agents and transport them across cells [119].”
Pommerolle, P., Laurent, P., Presne, C., Brazier, F., Jaureguy, M., Poulain, C., Flahaut, G., Mazouz, H., Brochot, É., Choukroun, G. J., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02580-4 · Cited by 3
Sharmin, E., Majumder, K., & Ahmed, S. F. (2025) · Scientific Reports · doi:10.1038/s41598-025-12690-4 · Cited by 2
“These results align with findings from the Moderna Phase 3 trial, which reported injection-site pain as the most common local adverse event, occurring in up to 83% of participants 10 .”
Mandatory Vaccination Against COVID-19: Twitter Poll Analysis on Public Health Opinion
Ritschl, V., Eibensteiner, F., Mosor, E., Omara, M., Sperl, L., Nawaz, F. A., Sai, C. S., Cenanovic, M., Devkota, H. P., Hriberšek, M., et al. (2022) · JMIR Formative Research · doi:10.2196/35754 · Cited by 4
Elastin-like peptides for efficient and safe delivery of mRNA
Li, F., Wang, Q., Wang, T., Xiong, C., Chen, Z., Ouyang, H., Lou, X., Xia, F., Wang, S., Wu, M., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114337 · Cited by 3
Immunogenicity of COVID-19 Vaccination in People Living with HIV: Progress and Challenges
Song, J., Shen, L., & Wang, F. (2023) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000073 · Cited by 3
Descriptive and Analytical Epidemiology
Sapkota, K. (2023) · Springer eBooks · doi:10.1007/978-3-031-41784-9_1 · Cited by 2
A novel Rift Valley fever vaccine
Bronder, S., & Sester, M. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00134-2 · Cited by 2
Key facts about the COVID-19 vaccination programme in the UK
Tang, S., & Morgan, K. (2021) · Journal of Paramedic Practice · doi:10.12968/jpar.2021.13.2.56 · Cited by 2
Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients
Schmieszek, J., Fuehner, T., Renger, I., Welte, T., Menne, J., Fuge, J., Klooster, M. P. V., Paul, A., Siegert, A., Borchina, D., et al. (2024) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.14137 · Cited by 2
The current landscape of mRNA therapy and the strategies for mRNA purification and dsRNA removal
Liu, J., Zang, J., Jing-Ru, X., Ran, X., Su, M., Zhang, W.-M., Ge, Z.-W., Sun, Q.-Y., & Ding, L. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01277-4 · Cited by 3
“The development and widespread use of COVID-19 mRNA vaccines represent the most significant achievement of mRNA technology, demonstrating strong effectiveness in reducing severe disease, hospitalization, and mortality during the pandemic [7, 8].”
Vaccination COVID-19 : technologies vaccinales, efficacité en vie réelle et spécificités
Lachâtre, M., & Launay, O. (2022) · Médecine et Maladies Infectieuses Formation · doi:10.1016/j.mmifmc.2022.07.001 · Cited by 7
Mateyka, L. M., Strobl, P. M., Jarosch, S., Scheu, S. J. C., Busch, D. H., & D’Ippolito, E. (2022) · Vaccines · doi:10.3390/vaccines10101617 · Cited by 2
Nafilyan, V., Bermingham, C., Ward, I., Morgan, J., Zaccardi, F., Khunti, K., Stanborough, J., & Banerjee, A. (2022) · medRxiv · doi:10.1101/2022.03.22.22272775 · Cited by 2
Fang, X., Tao, G., Zhou, H., & Zhou, Y. (2024) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2024.102632 · Cited by 3
Self-citationPrevalence and prognostic implications of myocardial injury across different waves of COVID-19
Peiró, Ó. M., Delgado-Cornejo, J. R., Sánchez-Giménez, R., Del-Moral-Ronda, V., Lal-Trehan, N., Rocamora-Horrach, M., Carrasquer, A., Peraire, J., Fort-Gallifa, I., & Bardajı́, A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1297824 · Cited by 4
Coggiola, M., Clemente, G., Frammartino, R., Grillo, E., Corradi, A., Corezzi, M., Kakaa, O., Paradisi, E., Tuffanelli, A., Pensamiento, M. C. A., et al. (2021) · La Medicina del Lavoro · doi:10.23749/mdl.v112i6.12124 · Cited by 2
Should people with chronic liver diseases be vaccinated against COVID-19?
Chen, L., Zeng, Q., Gong, Y., & Liang, F.-L. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i26.7959 · Cited by 2
Lau, C. S., Wong, M. S., Hoo, S. P., Heng, P. Y., Phua, S. K., & Aw, T. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00257 · Cited by 2
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.